William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on August 11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors that highlight Tenaya Therapeutics’ innovative approach in the field of gene therapy. The company’s use of mass spectrometry for measuring protein expression in cardiac tissue represents a significant advancement over traditional methods like western blot. This technique allows for the simultaneous quantification of hundreds of proteins, providing a more comprehensive and accurate assessment of protein expression levels.
Furthermore, the normalization process employed by Tenaya, which uses cardiac-specific proteins such as myosin, results in more consistent and reliable measurements. This is particularly important for genetic haploinsufficient diseases, where maintaining some level of normal protein expression is crucial. The expert insights from Dr. Michael Previs, who supports these methods, bolster confidence in Tenaya’s approach, suggesting that their innovative techniques could lead to better outcomes in gene therapy trials.
Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and PTC Therapeutics. According to TipRanks, Corwin has an average return of 3.8% and a 47.22% success rate on recommended stocks.